The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1 - Deficient ovarian tumors and can be exploited to improve treatment response in a mouse model

Gynecologic Oncology

Volumn 133, Issue 3, 2014, Pages 584-590

  Mantia Smaldone, Gina ^a   Ronner, Lukas ^b   Blair, Anne ^c   Gamerman, Victoria ^c   Morse, Christopher ^b   Orsulic, Sandra ^d   Rubin, Stephen ^a   Gimotty, Phyllis ^c   Adams, Sarah ^e  

^a FOX CHASE CANCER CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

BRCA; Host immunity; Immunomodulation; Ovarian cancer; Pegylated Liposomal Doxorubicin; T cells

Indexed keywords

BRCA1 PROTEIN; DOXORUBICIN; DOXOVES; FAS LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; UPREGULATION; WILD TYPE;

BRCA; HOST IMMUNITY; IMMUNOMODULATION; OVARIAN CANCER; PEGYLATED LIPOSOMAL DOXORUBICIN; T CELLS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOXORUBICIN; FEMALE; GENES, BRCA1; HUMANS; IMMUNOMODULATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901647977     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.03.565     Document Type: Article

References (14)

1. T. Pal, J. Permuth-Wey, J.A. Betts, J.P. Krischer, J. Fiorica, and H. Arango et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases Cancer 104 12 2005 2807 2816
2. I. Cass, R.L. Baldwin, T. Varkey, R. Moslehi, S.A. Narod, and B.Y. Karlan Improved survival in women with BRCA-associated ovarian carcinoma Cancer 97 9 2003 2187 2195
3. S.F. Adams, E.B. Marsh, W. Elmasri, S. Halberstadt, S. Vandecker, and M.D. Sammel et al. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer Gynecol Oncol 123 3 2011 486 491
4. I. Alagkiozidis, A. Facciabene, C. Carpenito, F. Benencia, Z. Jonak, and S. Adams et al. Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18 J Transl Med 7 2009 104
5. N. Casares, M.O. Pequignot, A. Tesniere, F. Ghiringhelli, S. Roux, and N. Chaput et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death J Exp Med 202 12 2005 1691 1701
6. M. Obeid, A. Tesniere, F. Ghiringhelli, G.M. Fimia, L. Apetoh, and J.L. Perfettini et al. Calreticulin exposure dictates the immunogenicity of cancer cell death Nat Med 13 1 2007 54 61
7. A. Cabanes, S. Even-Chen, J. Zimberoff, Y. Barenholz, E. Kedar, and A. Gabizon Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2 Clin Cancer Res 5 3 1999 687 693
8. S.F. Adams, D.A. Levine, M.G. Cadungog, R. Hammond, A. Facciabene, and N. Olvera et al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer Cancer 115 13 2009 2891 2902
9. L. Zhang, J.R. Conejo-Garcia, D. Katsaros, P.A. Gimotty, M. Massobrio, and G. Regnani et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 348 3 2003 203 213
10. B. Clarke, A.V. Tinker, C.H. Lee, S. Subramanian, M. van de Rijn, and D. Turbin et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss Mod Pathol 22 3 2009 393 402
11. S. Orsulic, Y. Li, R.A. Soslow, L.A. Vitale-Cross, J.S. Gutkind, and H.E. Varmus Induction of ovarian cancer by defined multiple genetic changes in a mouse model system Cancer Cell 1 1 2002 53 62
12. D. Xing, and S. Orsulic A mouse model for the molecular characterization of brca1-associated ovarian carcinoma Cancer Res 66 18 2006 8949 8953
13. D. Xing, and S. Orsulic A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance Proc Natl Acad Sci U S A 102 19 2005 6936 6941
14. M.H. Andersen, D. Schrama, P. Thor Straten, and J.C. Becker Cytotoxic T cells J Invest Dermatol 126 1 2006 32 41